ASCO 2013
Interviews and expert commentary from ASCO 2013 — study authors and key opinion leaders discuss the findings and their clinical implications.
Audio Journal of Oncology
MEK-inhibitor selumetinib doubles progression free survival in advanced uveal melanoma
CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Ca
13 June 2013
0:00
Audio Journal of Oncology
Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer
ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months — but have fewer side effec
24 March 2013
0:00
Audio Journal of Oncology
Androgen Blockade: 18 As Good As 36 Months In Radiotherapy-Treated Prostate Cancer
ORLANDO, FLORIDA—Patients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months
16 March 2013
0:00